QIAGEN

ISIN NL0015002CX3

 | 

WKN A40ZZU

Market cap (in EUR)
8,613 m
Country
Netherlands
Sector
Healthcare
Dividend yield
0.54%
 

Overview

Description

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Show more Show less
Healthcare Healthcare Equipment Diagnostics and Drug Delivery Devices Netherlands

Financials

Key metrics

Market capitalisation, EUR 8,613 m
EPS, EUR 1.68
P/B ratio 2.8
P/E ratio 25.1
Dividend yield 0.54%

Income statement (2024)

Revenue, EUR 1,829 m
Net income, EUR 77 m
Profit margin 4.23%
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.